Skip to main content

Advertisement

SpringerLink
Log in

The Humanistic and Economic Burden of Juvenile Idiopathic Arthritis in the era of Biologic Medication

  • Health Economics and Quality of Life (M Harrison, Section Editor)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Juvenile idiopathic arthritis (JIA) is a poorly understood, heterogeneous, incurable, inflammatory syndrome. Long-term outcomes are uncertain, and this painful condition can result in lifelong disability. JIA is associated with considerable financial and humanistic burden for those affected and the healthcare system. Early diagnosis and effective treatment are indicated to optimise outcomes. Modern treatment aims to achieve remission and preserve joint function by using disease-modifying antirheumatic drugs (DMARDs) early. DMARDs can be classified as conventional/traditional or biologic. Biologic medications may be more effective but cost approximately ten times more than traditional DMARDs. Decision-makers in healthcare are increasingly comparing the cost and consequences of alternative treatment strategies to guide resource allocation decisions. There have been few economic evaluations to date to guide medicines optimisation in JIA. This systematic review highlights the lack of existing evidence relating to the humanistic and economic burden of JIA in the era of biologic medication.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Thierry S, Fautrel B, Lemelle I, Guillemin F. Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine. 2014;81(2):112–7.

    Article  PubMed  Google Scholar 

  2. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–2.

    PubMed  Google Scholar 

  3. Gowdie P. Juvenile Idiopathic Arthritis (2012) [Internet]. 2012 [cited 2015 Jan 22]. Available from: http://www.slideshare.net/Dr_Padmesh/juvenile-idiopathic-arthritis-2012

  4. Martini A. It is time to rethink juvenile idiopathic arthritis classification and nomenclature. Ann Rheum Dis. 2012;71(9):1437–9.

    Article  PubMed  Google Scholar 

  5. Harrold LR, Salman C, Shoor S, Curtis JR, Asgari MM, Gelfand JM, et al. Incidence and prevalence of juvenile idiopathic arthritis among children in a managed care population, 1996–2009. J Rheumatol. 2013;40(7):1218–25.

    Article  PubMed  Google Scholar 

  6. Stoll ML, Cron RQ. Treatment of juvenile idiopathic arthritis: a revolution in care. Pediatr Rheumatol. 2014;12(1):13.

    Article  Google Scholar 

  7. Minden K, Niewerth M, Zink A, Seipelt E, Foeldvari I, Girschick H, et al. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatol Oxf Engl. 2012;51(8):1407–15.

    Article  CAS  Google Scholar 

  8. Wallace CA. Current management of juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol. 2006;20(2):279–300.

    Article  PubMed  Google Scholar 

  9. Cummins C, Connock M, Fry-Smith A, Burls A. A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept. Health Technol Assess Winch Engl. 2002;6(17):1–43.

    Google Scholar 

  10. Ungar WJ, Costa V, Burnett HF, Feldman BM, Laxer RM. The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: a systematic review. Semin Arthritis Rheum. 2013 Jan 18.

  11. Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med. 2008;148(2):124–34.

    Article  PubMed  Google Scholar 

  12. Kemper AR, Van Mater HA, Coeytaux RR, Williams Jr JW, Sanders GD. Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis. BMC Pediatr. 2012;12:29.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Seid M, Opipari L, Huang B, Brunner HI, Lovell DJ. Disease control and health-related quality of life in juvenile idiopathic arthritis. Arthritis Care Res. 2009;61(3):393–9.

    Article  Google Scholar 

  14. Drummond MF. Methods for the economic evaluation of health care programmes. Oxford University Press; 2005. 404 p.

  15. Krol M, Brouwer W, Rutten F. Productivity costs in economic evaluations: past, present, future. PharmacoEconomics. 2013;31(7):537–49.

    Article  PubMed  Google Scholar 

  16. Goodrich K, Kaambwa B, Al-Janabi H. The inclusion of informal care in applied economic evaluation: a review. Value Health J Int Soc Pharmacoecon Outcomes Res. 2012;15(6):975–81.

    Article  Google Scholar 

  17. Allaire SH, DeNardo BS, Szer IS, Meenan RF, Schaller JG. The economic impacts of juvenile rheumatoid arthritis. J Rheumatol. 1992;19(6):952–5.

    CAS  PubMed  Google Scholar 

  18. Palloni A. Reproducing inequalities: luck, wallets, and the enduring effects of childhood health. Demography. 2006;43(4):587–615.

    Article  PubMed  Google Scholar 

  19. Adam T, Evans DB, Koopmanschap MA. Cost-effectiveness analysis: can we reduce variability in costing methods? Int J Technol Assess Health Care. 2003;19(02):407–20.

    Article  PubMed  Google Scholar 

  20. Sleed M, Eccleston C, Beecham J, Knapp M, Jordan A. The economic impact of chronic pain in adolescence: methodological considerations and a preliminary costs-of-illness study. Pain. 2005;119(1–3):183–90.

    Article  PubMed  Google Scholar 

  21. Streisand R, Braniecki S, Tercyak KP, Kazak AE. Childhood illness-related parenting stress: the pediatric inventory for parents. J Pediatr Psychol. 2001;26(3):155–62.

    Article  CAS  PubMed  Google Scholar 

  22. Basu A, Meltzer D. Implications of spillover effects within the family for medical cost-effectiveness analysis. J Health Econ. 2005;24(4):751–73.

    Article  PubMed  Google Scholar 

  23. NICE. Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis | Guidance and guidelines | NICE [Internet]. 2002 [cited 2014 Sep 4]. Available from: http://www.nice.org.uk/Guidance/ta35

  24. NICE. Tocilizumab for the treatment of systemic juvenile idiopathic arthritis | Guidance and guidelines | NICE [Internet]. 2011 [cited 2014 Sep 2]. Available from: http://www.nice.org.uk/Guidance/ta238

  25. American College of Rheuatology. Recommendations for the treatment of juvenile idiopathic arthritis initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Atlanta: ACR; 2011.

    Google Scholar 

  26. Kemper AR, Coeytaux R, Sanders GD, Van Mater H, Williams JW, Gray RN, et al. Disease-modifying antirheumatic drugs (DMARDs) in children with juvenile idiopathic arthritis (JIA) [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 [cited 2013 May 1]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK65169/

  27. Sabik LM, Lie RK. Priority setting in health care: lessons from the experiences of eight countries. Int J Equity Health. 2008;7:4.

    Article  PubMed Central  PubMed  Google Scholar 

  28. NICE. Guide to the methods of technology appraisal [Internet]. NICE. 2013 [cited 2014 Jan 8]. Available from: http://www.nice.org.uk/

  29. Coffin PO, Sullivan SD. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann Intern Med. 2013;158(1):1–9.

    Article  PubMed  Google Scholar 

  30. Canadian Agency for, Drugs and Technologies, in Health. Guidelines for the Economic Evaluation of Health Technologies: Canada. Ottowa: CADTH;

  31. Ungar WJ, Prosser LA, Burnett HF. Values and evidence colliding: health technology assessment in child health. Expert Rev Pharmacoecon Outcomes Res. 2013;13(4):417–9.

    Article  PubMed  Google Scholar 

  32. Sung L, Greenberg ML, Doyle JJ, Young NL, Ingber S, Rubenstein J, et al. Construct validation of the health utilities index and the child health questionnaire in children undergoing cancer chemotherapy. Br J Cancer. 2003;88(8):1185–90.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  33. Furlong WJ, Feeny DH, Torrance GW, Barr RD. The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies. Ann Med. 2001;33(5):375–84.

    Article  CAS  PubMed  Google Scholar 

  34. The University of Sheffield. Publications and Presentations - Paediatric QoL - Measuring & Valuing Health - HEDS - Sections - ScHARR - The University of Sheffield [Internet]. 2014 [cited 2015 Jan 22]. Available from: https://www.shef.ac.uk/scharr/sections/heds/mvh/paediatric/pubandpres

  35. Prince FHM, van Suijlekom-Smit LWA. Cost of biologics in the treatment of juvenile idiopathic arthritis: a factor not to be overlooked. Paediatr Drugs. 2013;15(4):271–80.

    Article  PubMed  Google Scholar 

  36. Minden K. What are the costs of childhood-onset rheumatic disease? Best Pract Res Clin Rheumatol. 2006;20(2):223–40.

    Article  PubMed  Google Scholar 

  37. Otten MH, Anink J, Prince FH, Twilt M, Vastert SJ, Cate RT, et al. PReS-FINAL-2146: trends in prescription of biologics and outcomes of juvenile idiopathic arthritis; results of the Dutch national arthritis and biologicals in children register. Pediatr Rheumatol. 2013;11 Suppl 2:158.

    Article  Google Scholar 

  38. Butbul Aviel Y, Stremler R, Benseler SM, Cameron B, Laxer RM, Ota S, et al. Sleep and fatigue and the relationship to pain, disease activity and quality of life in juvenile idiopathic arthritis and juvenile dermatomyositis. Rheumatol Oxf Engl. 2011;50(11):2051–60.

    Article  Google Scholar 

  39. Békési A, Török S, Kökönyei G, Bokrétás I, Szentes A, Telepóczki G, et al. Health-related quality of life changes of children and adolescents with chronic disease after participation in therapeutic recreation camping program. Health Qual Life Outcomes. 2011;9:43.

    Article  PubMed Central  PubMed  Google Scholar 

  40. Prince FHM, de Bekker-Grob EW, Twilt M, van Rossum MAJ, Hoppenreijs EPAH, ten Cate R, et al. An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis: results from the Dutch arthritis and biologicals in children register. Rheumatol Oxf Engl. 2011;50(6):1131–6.

    Article  CAS  Google Scholar 

  41. Ruperto N, Lovell DJ, Li T, Sztajnbok F, Goldenstein-Schainberg C, Scheinberg M, et al. Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care Res. 2010;62(11):1542–51.

    Article  Google Scholar 

  42. Grootenhuis MA, Koopman HM, Verrips EGH, Vogels AGC, Last BF. Health-related quality of life problems of children aged 8–11 years with a chronic disease. Dev Neurorehabil. 2007;10(1):27–33.

    Article  CAS  PubMed  Google Scholar 

  43. Norrby U, Nordholm L, Andersson-Gäre B, Fasth A. Health-related quality of life in children diagnosed with asthma, diabetes, juvenile chronic arthritis or short stature. Acta Paediatr Oslo Nor. 1992;95(4):450–6. 2006 Apr.

    Google Scholar 

  44. Riddle R, Ryser CN, Morton AA, Sampson JD, Browne RH, Punaro MG, et al. The impact on health-related quality of life from non-steroidal anti-inflammatory drugs, methotrexate, or steroids in treatment for juvenile idiopathic arthritis. J Pediatr Psychol. 2006;31(3):262–71.

    Article  PubMed  Google Scholar 

  45. Sawyer MG, Whitham JN, Roberton DM, Taplin JE, Varni JW, Baghurst PA. The relationship between health-related quality of life, pain and coping strategies in juvenile idiopathic arthritis. Rheumatol Oxf Engl. 2004;43(3):325–30.

    Article  CAS  Google Scholar 

  46. Palermo TM, Kiska R. Subjective sleep disturbances in adolescents with chronic pain: relationship to daily functioning and quality of life. J Pain Off J Am Pain Soc. 2005;6(3):201–7.

    Article  Google Scholar 

  47. Selvaag AM, Flatø B, Lien G, Sørskaar D, Vinje O, Førre Ø. Measuring health status in early juvenile idiopathic arthritis: determinants and responsiveness of the child health questionnaire. J Rheumatol. 2003;30(7):1602–10.

    PubMed  Google Scholar 

  48. Klotsche J, Minden K, Thon A, Ganser G, Urban A, Horneff G. Improvement in health-related quality of life for children with juvenile idiopathic arthritis after start of treatment with etanercept. Arthritis Care Res. 2014;66(2):253–62.

    Article  CAS  Google Scholar 

  49. Lundberg V, Lindh V, Eriksson C, Petersen S, Eurenius E. Health-related quality of life in girls and boys with juvenile idiopathic arthritis: self- and parental reports in a cross-sectional study. Pediatr Rheumatol. 2012;10(1):33.

    Article  Google Scholar 

  50. Thornton J, Lunt M, Ashcroft DM, Baildam E, Foster H, Davidson J, et al. Costing juvenile idiopathic arthritis: examining patient-based costs during the first year after diagnosis. Rheumatol Oxf Engl. 2008;47(7):985–90.

    Article  CAS  Google Scholar 

  51. Haapasaari J, Kautiainen HJ, Isomäki HA, Hakala M. Etanercept does not essentially increase the total costs of the treatment of refractory juvenile idiopathic arthritis. J Rheumatol. 2004;31(11):2286–9.

    PubMed  Google Scholar 

  52. Bernatsky S, Duffy C, Malleson P, Feldman DE, St Pierre Y, Clarke AE. Economic impact of juvenile idiopathic arthritis. Arthritis Rheum. 2007;57(1):44–8.

    Article  PubMed  Google Scholar 

  53. Yucel IK, Seyahi E, Kasapcopur O, Arisoy N. Economic impact of juvenile idiopathic arthritis and familial Mediterranean fever. Rheumatol Int. 2012;32(7):1955–62.

    Article  PubMed Central  PubMed  Google Scholar 

  54. Ens A, Lang B, Ramsey S, Stringer E, Huber AM. The financial burden of juvenile idiopathic arthritis: a Nova Scotia experience. Pediatr Rheumatol Online J. 2013;11(1):24.

    Article  PubMed Central  PubMed  Google Scholar 

  55. The Campbell and Cochrane Economics Methods Group. CCEMG - EPPI-Centre Cost Converter [Internet]. 2014. Available from: http://eppi.ioe.ac.uk/costconversion/Default.aspx

  56. Bernatsky S, Rosenberg AM, Oen KG, Duffy CM, Ramsey-Goldman R, Labrecque J, et al. Malignancies in juvenile idiopathic arthritis: a preliminary report. J Rheumatol. 2011;38(4):760–3.

    Article  PubMed  Google Scholar 

  57. Short ME, Goetzel RZ, Pei X, Tabrizi MJ, Ozminkowski RJ, Gibson TB, et al. How accurate are self-reports? analysis of self-reported health care utilization and absence when compared with administrative data. J Occup Environ Med. 2009;51(7):786–96.

    Article  PubMed Central  PubMed  Google Scholar 

  58. Lairson DR, Basu R, Begley CE, Reynolds T. Concordance of survey and billing data in a study of outpatient healthcare cost and utilization among epilepsy patients. Epilepsy Res. 2009;87(1):59–69.

    Article  PubMed  Google Scholar 

  59. Mann C. Observational research methods. Research design II: cohort, cross sectional, and case-control studies. Emerg Med J EMJ. 2003;20(1):54–60.

    Article  CAS  Google Scholar 

  60. Zhang W, Gignac MM, Beaton D, Tang K, Anis AH. Productivity loss due to presenteeism among patients with arthritis: estimates from 4 instruments. J Rheumatol. 2010;37(9):1805–14.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Wendy Gidman, Rachel Meacock and Deborah Symmons declare no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Centre for Health Economics, University of Manchester, Oxford Road, Manchester, UK

    Wendy Gidman & Rachel Meacock

  2. Arthritis Research Centre for Epidemiology, University of Manchester, Oxford Road, Manchester, UK

    Deborah Symmons

Authors
  1. Wendy Gidman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rachel Meacock
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Deborah Symmons
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wendy Gidman.

Additional information

This article is part of the Topical Collection on Health Economics and Quality of Life

Appendices

Appendix 1

Fig. 1
figure 1

Search strategy

Full size image

Appendix 2

Fig. 2
figure 2

Flow chart summarising paper identification process

Full size image

Appendix 3

Table 2 Generic health-related quality of life outcome measures
Full size table

Appendix 4

Table 3 Summary of papers reporting the humanistic burden of JIA
Full size table

Appendix 5

Table 4 Summary of papers reporting the economic burden of JIA
Full size table

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gidman, W., Meacock, R. & Symmons, D. The Humanistic and Economic Burden of Juvenile Idiopathic Arthritis in the era of Biologic Medication. Curr Rheumatol Rep 17, 31 (2015). https://doi.org/10.1007/s11926-015-0508-1

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11926-015-0508-1

Keywords

Search

Navigation